CD80 and breast cancer: In another phase I study, a human leukocyte antigen (HLA)-A2+, HER2/neu(+) allogeneic MDA-MB-231 BC cell line was modified to express the costimulatory molecule B7-1 (CD80) and used as a vaccine to treat stage IV BC patients (64).